Burton Daniel D. bought $204,525 worth of shares (26,200 units at $7.81), increasing direct ownership by 2% to 1,172,623 units (SEC Form 4)

$HCAT
Computer Software: Programming Data Processing
Technology
Get the next $HCAT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burton Daniel D.

(Last) (First) (Middle)
C/O HEALTH CATALYST, INC.
10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)
SOUTH JORDAN UT 84095

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/27/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/27/2024 P 26,200 A $7.8063 1,172,623 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Benjamin Landry, as Attorney-in-Fact 02/27/2024
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $HCAT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HCAT

DatePrice TargetRatingAnalyst
1/8/2025$9.00Sector Weight → Overweight
KeyBanc Capital Markets
4/10/2024Overweight → Sector Weight
KeyBanc Capital Markets
1/3/2024$14.00Overweight
Barclays
1/3/2024$11.00In-line → Outperform
Evercore ISI
12/13/2023$14.00 → $11.00Neutral → Overweight
JP Morgan
11/13/2023$12.00 → $11.00Neutral → Overweight
Piper Sandler
8/1/2023$16.00Overweight
Cantor Fitzgerald
5/10/2023Outperform → Mkt Perform
Raymond James
More analyst ratings

$HCAT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Health Catalyst Announces ~$5 Million Stock Repurchase

    SALT LAKE CITY, March 11, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has repurchased shares of its common stock ("Common Stock") in an aggregate amount of approximately $5 million. These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to $40 million o

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Signature Healthcare to Enhance Analytics by Leveraging Health Catalyst Ignite™

    SALT LAKE CITY, Feb. 27, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a multi-year agreement with Signature Healthcare, an integrated healthcare delivery system serving Southeastern Massachusetts. Signature Healthcare is collaborating with Health Catalyst to integrate data resource queries and unlock referral-related data powered by Health Catalyst Ignite™, a modern data and analytics ecosystem. Ignite integrates best-in-class cross

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Health Catalyst Reports Fourth Quarter and Year End 2024 Results

    SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024. "For the full year 2024, I am pleased to share that we achieved strong performance across our business, including total revenue of $307 million and Adjusted EBITDA of $26 million. Additionally, I am encouraged with our Technology segment, which had revenue of $195 million for full-year 2024 and $52 million for the fourth quarter of 2024, which represents 10% growth year-over-year. I am pleased with this pr

    $HCAT
    Computer Software: Programming Data Processing
    Technology

$HCAT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HCAT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$HCAT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HCAT
SEC Filings

See more

$HCAT
Leadership Updates

Live Leadership Updates

See more
  • Modern Health Welcomes Adam Brown as Chief Financial Officer

    Strengthens Executive Team with Seasoned Healthcare Finance Leader Modern Health, a leading global workplace mental health platform, today announces the appointment of Adam Brown as Chief Financial Officer. With an extensive background in healthcare finance and operations, including significant experience scaling high-growth healthcare technology companies, Brown brings deep industry expertise to the company. "Adam is a valued addition to Modern Health's leadership team, and we are thrilled to welcome him on board. His impressive track record and deep understanding of both public and private markets strengthens our executive bench as we continue to execute our vision," said Gyre Renwick

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Health Catalyst Signs Definitive Agreement to Acquire Upfront Healthcare Services

    SALT LAKE CITY, Jan. 13, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. ("Upfront"), a next-generation patient engagement platform provider. Health Catalyst anticipates the acquisition will close in the first quarter of 2025.Upfront provides a market-leading patient activation and engagement platform and a proprietary strategic marketing analytics and content personalization solution for healthcare enterprises. Upfront's automated patient acquisition and retention solu

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Nationally Recognized Healthcare Executive Dr. Jill Hoggard Green Joins Health Catalyst Board of Directors

    SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jill Hoggard Green, RN, BSN, MS, PhD, FAAN, former Chief Executive Officer of The Queen's Health Systems, has been appointed to serve as a member of Health Catalyst's board of directors ("Board") and a member of its Compensation Committee, effective December 1, 2024. "Jill has been an extraordinary leader throughout her career. With an impressive tenure in hea

    $HCAT
    Computer Software: Programming Data Processing
    Technology

$HCAT
Financials

Live finance-specific insights

See more
  • Health Catalyst Reports Fourth Quarter and Year End 2024 Results

    SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024. "For the full year 2024, I am pleased to share that we achieved strong performance across our business, including total revenue of $307 million and Adjusted EBITDA of $26 million. Additionally, I am encouraged with our Technology segment, which had revenue of $195 million for full-year 2024 and $52 million for the fourth quarter of 2024, which represents 10% growth year-over-year. I am pleased with this pr

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Health Catalyst to Announce Fourth Quarter and Full Year 2024 Operating Results and Host Conference Call on Wednesday, February 26, 2025

    SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and full year 2024 operating results on Wednesday, February 26, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day. Conference Call Details The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID "HCATQ424." A live audio webcast will be available online at https://ir.hea

    $HCAT
    Computer Software: Programming Data Processing
    Technology
  • Health Catalyst Reports Third Quarter 2024 Results

    SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2024. "For the third quarter of 2024, I am pleased with our strong financial results, including total revenue of $76.4 million and Adjusted EBITDA of $7.3 million, with these results exceeding the mid-point of our quarterly guidance on each metric. This financial performance continues to demonstrate our ability to scale as we remain focused on driving profitable growth. We are encouraged with our bookings results through Q3

    $HCAT
    Computer Software: Programming Data Processing
    Technology

$HCAT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more